About eTheRNA
Advanced Technology Boosting Immunotherapy
eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases. We employ messenger RNA to unleash and boost a patient’s immune response against a tumor or infectious agent. Research shows that this approach results in long lasting clinical remission in cancer patients and protective immunity against infections.
eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.
What We Do
Immunotherapies
Contract Manufacturing
Newsroom
Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million
Niel (Belgium)
- Accelerate development of novel mRNA vaccine for hard-to-treat cancers
- Clinical trial to commence end of 2021
Niel (Belgium) eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies as off-the shelf products for the treatment of cancer and infectious diseases, announces the award of a TIGER grant of EUR 6.9 million from the EU commission. The grant was awarded to a consortium led by eTheRNA and will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic Human Papillomavirus strain 16 positive (HPV16+) cancers such as head and neck cancer, cervical cancer, anogenital cancer.
// eTheRNA
WE'D LIKE TO HEAR FROM YOU
Galileilaan 19, 2845 Niel, Belgium
Our Address
Our Mailbox
+32 3 369 17 40
Our Phone
© 2020 Etherna | Studio Hanswijk